Alcoholism is a global problem with approximately 5-10% of the world's population demonstrating alcohol-related diseases. One of the most severe consequences of alcohol dependence is the withdrawal syndrome. This review assessed the effects of psychotropic analgesic nitrous oxide (PAN) in treating alcohol withdrawal. All trials were conducted in in-patient settings although PAN is also administered in outpatient settings. The review found that PAN is as effective as sedatives for managing mild to moderate alcohol withdrawal states. Nonetheless, it does not provide strong evidence in favour of the benefits or harms of using PAN over sedatives in managing acute alcohol withdrawal. Further high quality trials should be done before these findings can be confirmed.
Psychotropic analgesic nitrous oxide for alcoholic withdrawal states
Have your say!
'Your views on The Cochrane Library: survey'
Published Online:
October 8, 2008
Health topics:
More like this
- Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings
- The potential risks and high cost of using opioid blocking drugs during heavy sedation or anaesthesia to bring on withdrawal outweigh the benefits
- Baclofen (Lioresal) is a promising treatment for alcohol withdrawal syndrome
- Buprenorphine is more effective than clonidine or lofexidine, and may have advantages over methadone, for the management of opioid withdrawal.
- Methadone at tapered doses for the management of opioid withdrawal
